Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Clinical trial NCT02610140 · COMPLETED
Trial details
- NCT number
- NCT02610140
- Sponsor
- Bayer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-12-03
- Primary completion
- 2017-05-31
- Enrollment
- 248
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.